文献速递类风湿关节炎

类风湿关节炎患者中PROMIS-29在MDHAQ FAST4或2011纤维肌痛标准筛查阳性或阴性时的表现

PROMIS-29 in rheumatoid arthritis patients who screen positive or negative for fibromyalgia on MDHAQ FAST4 (fibromyalgia assessment screening tool) or 2011 fibromyalgia criteria.
PubMed 文献 · Semin Arthritis Rheum · 2024-01-18

横断面研究纳入213例类风湿关节炎患者,比较PROMIS-29 T评分与人群常模及纤维肌痛筛查阳性与阴性患者的差异,并分析PROMIS-29与MDHAQ评分的相关性。结果显示MDHAQ与PROMIS-29各域高度相关,MDHAQ可有效评估健康相关生活质量并提供FAST4筛查等增量医学信息。

要点

  • 类风湿关节炎患者中PROMIS-29 7个域与MDHAQ对应评分高度相关(|rho|≥0.62,p<0.001)。
  • 纤维肌痛筛查阳性较阴性患者PROMIS-29 T评分中位数在6/7个域差异更大,26-29%患者状态更差。
  • MDHAQ可有效评估健康相关生活质量,并提供FAST4纤维肌痛筛查等增量医学信息。

核心结论

  • PROMIS-29 7个域与MDHAQ评分高度相关,MDHAQ可有效评估健康相关生活质量并提供FAST4筛查等增量医学信息。
  • 结果提示在解读PROMIS-29 T评分时评估纤维肌痛等合并症的重要性。

研究设计与样本

  • 横断面研究,在一次常规访视中纳入213例类风湿关节炎患者,完成MDHAQ、PROMIS-29及参考2011纤维肌痛标准。
  • 比较类风湿关节炎患者与人群常模、以及基于MDHAQ/FAST4和参考标准判定的纤维肌痛阳性与阴性患者的PROMIS-29 T评分。
  • 采用Spearman相关和多元回归分析PROMIS-29 T评分与对应MDHAQ评分的可能关联。

主要发现

  • 纤维肌痛阳性较阴性类风湿关节炎患者PROMIS-29 T评分中位数在26-29%患者中显示临床和统计学显著更差状态。
  • 在6/7个域中,纤维肌痛阳性与阴性患者间的差异大于类风湿关节炎患者与人群常模间的差异。
  • MDHAQ评分与PROMIS-29各7个对应域显著相关(|rho|≥0.62,p<0.001)。
  • 线性回归中MDHAQ评分可解释PROMIS-29 T评分变异的55-73%,PROMIS-29 T评分可解释MDHAQ评分变异的56%-70%。

关键数值与推荐

  • PROMIS-29 T评分覆盖7个域:躯体功能、疼痛、疲劳、焦虑、抑郁、睡眠质量和社会参与。
  • 纤维肌痛筛查基于MDHAQ/FAST4指数和参考2011纤维肌痛标准。
  • MDHAQ与PROMIS-29对应域相关系数|rho|≥0.62(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PROMIS-29 T-scores query health-related quality of life (HRQL) in 7 domains, physical function, pain, fatigue, anxiety, depression, sleep quality, and social participation, to establish population norms. An MDHAQ (multidimensional health assessment questionnaire) scores these 7 domains and includes medical information such as a FAST4 (fibromyalgia assessment screening tool) index. We analyzed PROMIS-29 T-scores in rheumatoid arthritis (RA) patients vs population norms and for positive vs negative fibromyalgia (FM) screens and compared PROMIS-29 T-scores to MDHAQ scores to assess HRQL. METHODS: A cross-sectional study was performed at one routine visit of 213 RA patients, who completed MDHAQ, PROMIS-29, and reference 2011 FM Criteria. PROMIS-29 T-scores were compared in RA vs population norms and in FM+ vs FM- RA patients, based on MDHAQ/FAST4 and reference criteria. Possible associations between PROMIS-29 T-scores and corresponding MDHAQ scores were analyzed using Spearman correlations and multiple regressions. RESULTS: Median PROMIS-29 T-scores indicated clinically and statistically significantly poorer status in 26-29% FM+ vs FM- RA patients, with larger differences than in RA patients vs population norms for 6/7 domains. MDHAQ scores were correlated significantly with each of 7 corresponding PROMIS-29 domains (|rho|≥0.62, p<0.001). Linear regressions explained 55-73% of PROMIS-29 T-score variation by MDHAQ scores and 56%-70% of MDHAQ score variation by PROMIS-29 T-scores. CONCLUSIONS: Scores for 7 PROMIS-29 domains and MDHAQ were highly correlated. The MDHAQ is effective to assess HRQL and offers incremental medical information, including FAST4 screening. The results indicate the importance of assessing comorbidities such as fibromyalgia screening in interpreting PROMIS-29 T-scores.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Gibson KA, Kaplan RM, Pincus T, et al. PROMIS-29 in rheumatoid arthritis patients who screen positive or negative for fibromyalgia on MDHAQ FAST4 (fibromyalgia assessment screening tool) or 2011 fibromyalgia criteria. Semin Arthritis Rheum. 2024. PMID: 38360468. doi:10.1016/j.semarthrit.2024.152361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。